Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fortress Biotech (FBIO) Income from Continuing Operations: 2009-2024

Historic Income from Continuing Operations for Fortress Biotech (FBIO) over the last 16 years, with Dec 2024 value amounting to -$120.9 million.

  • Fortress Biotech's Income from Continuing Operations rose 133.03% to $8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.2 million, marking a year-over-year increase of 36.67%. This contributed to the annual value of -$120.9 million for FY2024, which is 21.60% up from last year.
  • According to the latest figures from FY2024, Fortress Biotech's Income from Continuing Operations is -$120.9 million, which was up 21.60% from -$154.2 million recorded in FY2023.
  • In the past 5 years, Fortress Biotech's Income from Continuing Operations registered a high of -$103.0 million during FY2020, and its lowest value of -$213.9 million during FY2022.
  • In the last 3 years, Fortress Biotech's Income from Continuing Operations had a median value of -$154.2 million in 2023 and averaged -$163.0 million.
  • In the last 5 years, Fortress Biotech's Income from Continuing Operations slumped by 60.07% in 2021 and then climbed by 27.94% in 2023.
  • Fortress Biotech's Income from Continuing Operations (Yearly) stood at -$103.0 million in 2020, then crashed by 60.07% to -$164.9 million in 2021, then declined by 29.76% to -$213.9 million in 2022, then rose by 27.94% to -$154.2 million in 2023, then grew by 21.60% to -$120.9 million in 2024.